Terms: = Lung cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras
1286 results:
1. Emerging role of tumor suppressing microRNAs as therapeutics in managing non-small cell lung cancer.
Singh S; Saxena S; Sharma H; Paudel KR; Chakraborty A; MacLoughlin R; Oliver BG; Gupta G; Negi P; Singh SK; Dua K
Pathol Res Pract; 2024 Apr; 256():155222. PubMed ID: 38452582
[TBL] [Abstract] [Full Text] [Related]
2. k-ras(V12) differentially affects the three Akt isoforms in lung and pancreatic carcinoma cells and upregulates E-cadherin and NCAM via Akt3.
Geißert R; Lammert A; Wirth S; Hönig R; Lohfink D; Unger M; Pek D; Schlüter K; Scheftschik T; Smit DJ; Jücker M; Menke A; Giehl K
Cell Commun Signal; 2024 Jan; 22(1):85. PubMed ID: 38291468
[TBL] [Abstract] [Full Text] [Related]
3. Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.
Baranyi M; Molnár E; Hegedűs L; Gábriel Z; Petényi FG; Bordás F; Léner V; Ranđelović I; Cserepes M; Tóvári J; Hegedűs B; Tímár J
Br J Cancer; 2024 Apr; 130(6):1059-1072. PubMed ID: 38278976
[TBL] [Abstract] [Full Text] [Related]
4. Clinical-Molecular characteristics and Post-Translational modifications of colorectal cancer in north China: Implications for future targeted therapies.
Chi Y; Yuan H; Fan Q; Wang Z; Niu Z; Yu J; Yuan D
Gene; 2024 Mar; 899():148134. PubMed ID: 38185290
[TBL] [Abstract] [Full Text] [Related]
5. The diagnosis and treatment for primary cardiac angiosarcoma with n-ras gene mutation and MSI-L: A case report and review of the literature.
Sun J; Wei T; Sun B; Su J; Liu H; Wang D; Li X
Medicine (Baltimore); 2023 Dec; 102(51):e36682. PubMed ID: 38134104
[TBL] [Abstract] [Full Text] [Related]
6. Runx3 Restoration Regresses k-ras-Activated Mouse lung cancers and Inhibits Recurrence.
Lee JY; Lee JW; Park TG; Han SH; Yoo SY; Jung KM; Kim DM; Lee OJ; Kim D; Chi XZ; Kim EG; Lee YS; Bae SC
Cells; 2023 Oct; 12(20):. PubMed ID: 37887282
[TBL] [Abstract] [Full Text] [Related]
7. ITPR1-AS1 promotes small cell lung cancer metastasis by facilitating P21
Zhang Q; Zheng L; Bai Y; Su C; Che Y; Xu J; Sun K; Ni J; Huang L; Shen Y; Jia L; Xu L; Yin R; Li M; Hu J
Cancer Lett; 2023 Nov; 577():216426. PubMed ID: 37820992
[TBL] [Abstract] [Full Text] [Related]
8. CRISPR-mediated reversion of oncogenic KRAS mutation results in increased proliferation and reveals independent roles of Ras and mTORC2 in the migration of A549 lung cancer cells.
Werner AN; Kumar AI; Charest PG
Mol Biol Cell; 2023 Dec; 34(13):ar128. PubMed ID: 37729017
[TBL] [Abstract] [Full Text] [Related]
9. The possibility of mutations of RAS signaling genes and/or TP53 in combination as a negative prognostic impact on pathological stage I non-small cell lung cancer.
Honda T; Seto K; Endo S; Takemoto A; Tanimoto K; Kobayashi M; Kitano M; Sakakibara R; Mitsumura T; Ishibashi H; Inazawa J; Tanaka T; Miyazaki Y; Okubo K
Cancer Med; 2023 Oct; 12(19):19406-19413. PubMed ID: 37712717
[TBL] [Abstract] [Full Text] [Related]
10. The inhibition of pancreatic cancer progression by k-ras-overexpressing mesenchymal stem cell-derived secretomes.
Huo Q; Li K; Sun X; Zhuang A; Minami K; Tamari K; Ogawa K; Fishel ML; Li BY; Yokota H
Sci Rep; 2023 Sep; 13(1):15036. PubMed ID: 37699930
[TBL] [Abstract] [Full Text] [Related]
11. A new ferrocene derivative blocks k-ras localization and function by oxidative modification at His95.
Rehl KM; Selvakumar J; Pitsch RL; Hoang D; Arumugam K; Harshman SW; Gorfe AA; Cho KJ
Life Sci Alliance; 2023 Nov; 6(11):. PubMed ID: 37666666
[TBL] [Abstract] [Full Text] [Related]
12. Small molecular inhibitors for KRAS-mutant cancers.
Wu X; Song W; Cheng C; Liu Z; Li X; Cui Y; Gao Y; Li D
Front Immunol; 2023; 14():1223433. PubMed ID: 37662925
[TBL] [Abstract] [Full Text] [Related]
13. Improving Access and Timeliness of Early Palliative Care Specialist Assessment for Patients With Advanced lung cancer in a Rapid Assessment Clinic.
O'Neill H; Robertson M; Kain D; Syed I; Pauli G; Parker CM; Digby GC
J Palliat Med; 2023 Oct; 26(10):1365-1373. PubMed ID: 37437122
[No Abstract] [Full Text] [Related]
14. Development and evaluation of a customized checklist to assess the quality control of disease registry systems of Tehran, the capital of Iran in 2021.
Barzin M; Sabbaghi H; Kamfar S; Seifi A; Hajipour M; Siri FH; Mir-Moeini E; Gharajeh A; Ferdosifard N; Panahi M; Nazari SSH; Atatalab FF; Etemad K
BMC Health Serv Res; 2023 Jul; 23(1):726. PubMed ID: 37403074
[TBL] [Abstract] [Full Text] [Related]
15. Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations.
Aoki K; Nishito Y; Motoi N; Arai Y; Hiraoka N; Shibata T; Sonobe Y; Kayukawa Y; Hashimoto E; Takahashi M; Fujii E; Nishizawa T; Fukuda H; Ohashi K; Arai K; Mizoguchi Y; Yoshida Y; Watanabe SI; Yamashita M; Kitano S; Sakamoto H; Nagata Y; Mitsumori R; Ozaki K; Niida S; Kanai Y; Hirayama A; Soga T; Maruyama T; Tsukada K; Yabuki N; Shimada M; Kitazawa T; Natori O; Sawada N; Kato A; Yoshida T; Yasuda K; Mizuno H; Tsunoda H; Ochiai A
Cancer Res Commun; 2023 Jun; 3(6):1026-1040. PubMed ID: 37377611
[TBL] [Abstract] [Full Text] [Related]
16. Clinicopathological Features and Prognosis of lung Adenocarcinoma Patients With k-ras Gene Mutation.
Sun D; Liu Y; Li P; Yang P; Yu G
Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):406-413. PubMed ID: 37338109
[TBL] [Abstract] [Full Text] [Related]
17. Evaluation of
Lastraioli E; Bettiol A; Iorio J; Limatola E; Checcacci D; Parisi E; Bianchi C; Arcangeli A; Iannopollo M; Di Costanzo F; Di Lieto M
Cells; 2023 May; 12(11):. PubMed ID: 37296579
[TBL] [Abstract] [Full Text] [Related]
18. Financial Toxicity in Patients With Resected lung cancer.
Deboever N; Eisenberg M; Hofstetter WL; Mehran RJ; Rice DC; Roth J; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL; Antonoff MB; Rajaram R
Ann Surg; 2023 Dec; 278(6):1038-1044. PubMed ID: 37249193
[TBL] [Abstract] [Full Text] [Related]
19. Establishment of a novel experimental system using single cell-derived pleomorphic rhabdomyosarcoma cell lines expressing k-rasG12V and deficient in p53.
Saito H; Suzuki N
Exp Anim; 2023 Nov; 72(4):446-453. PubMed ID: 37081671
[TBL] [Abstract] [Full Text] [Related]
20. Identification of novel peptide inhibitors for oncogenic KRAS G12D as therapeutic options using mutagenesis-based remodeling and MD simulations.
Samad A; Khurshid B; Mahmood A; Rehman AU; Khalid A; Abdalla AN; Algarni AS; Wadood A
J Biomol Struct Dyn; 2023; 41(22):13425-13437. PubMed ID: 37010994
[TBL] [Abstract] [Full Text] [Related]
[Next]
